Meltzer E O, Orgel H A, Bush R K, Haltom J R, Metzger W J, Moss B A, Mitchell D Q, Ballas Z K, Seltzer J M, Shapiro G G
Allergy and Asthma Medical Group and Research Center, San Diego, California 92123.
Ann Allergy. 1990 Jun;64(6):536-40.
A new formulation of intranasal flunisolide containing less propylene glycol was compared with the original formulation for efficacy and acceptability in more than 200 patients with symptoms of perennial allergic rhinitis. In this multicenter, randomized, double-blind, parallel group study, symptomatic patients were treated with either the new or the original formulation of 0.025% solution of intranasal flunisolide for 4 weeks to provide 200 micrograms flunisolide daily. Both formulations were highly effective in decreasing symptom scores as evident from patient diary reports before and after treatment (P less than .001). Similarly, nasal airflow was improved with each treatment as measured by anterior rhinomanometry (P less than .0002) and the number of patients with nasal eosinophilia decreased (P less than .01). Finally, fewer patients using the new formulation reported nasal burning or stinging and the acceptability rating of the new formulation was higher.
将一种含丙二醇较少的新剂型鼻内氟尼缩松与原剂型在200多名患有常年性变应性鼻炎症状的患者中进行疗效和可接受性比较。在这项多中心、随机、双盲、平行组研究中，有症状的患者用新剂型或原剂型的0.025%鼻内氟尼缩松溶液治疗4周，每日提供200微克氟尼缩松。从治疗前后患者日记报告来看，两种剂型在降低症状评分方面均非常有效（P<0.001）。同样，通过前鼻测压法测量，每次治疗后鼻气流均得到改善（P<0.0002），鼻嗜酸性粒细胞增多的患者数量减少（P<0.01）。最后，使用新剂型报告有鼻烧灼感或刺痛感的患者较少，新剂型的可接受性评分更高。
